3 completed. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
Follow BAX 855: new trials by email Literature Review of BAX 855 trials Research Report on BAX 855
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A Efanesoctocog alfa, Octocog alfa, Rurioctocog alfa pegol - Hemophilia A | Phase 1 | Completed | Sanofi | 13 | 2021-08-11 | 2025-09-18 |
| Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII) Damoctocog-alfa-pegol (BAY94-9027, Jivi), Rurioctocog alfa pegol (Adynovi) - Hemophilia A | Phase 1 | Completed | Bayer | 18 | 2019-08-08 | 2020-12-21 |
| BAX 855 Dose-Escalation Safety Study Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, PEGylated Recombinant Factor VIII - Hemophilia A | Phase 1 | Completed | Baxalta now part of Shire | 19 | 2011-09-30 | 2021-05-05 |
Hemophilia A (3)
Baxalta now part of Shire (1) · Bayer (1) · Sanofi (1)
Bulgaria (3) · Germany (1) · Japan (1) · United Kingdom (1)
PMID 26157075, PMID 32974838, PMID 37538505
2018 (1)